Site Editor
Gregory J. Riely, MD, PhD
Gregory J. Riely, MD, PhD
Posted: Monday, July 1, 2024
Patients with EGFR-mutant, advanced non–small cell lung cancer (NSCLC) have shown improvements in progression-free survival following treatment with the bispecific antibody amivantamab-vmjw plus the third-generation EGFR tyrosine kinase inhibitor lazertinib; however, outcomes for patients in high-risk groups are not well understood. In a study presented at the 2024 Annual American Society of Clinical Oncology (ASCO) Annual Meeting (Abstract 8504), Enriqueta Felip, MD, PhD, of the Vall d’Hebron University Hospital and Vall d’Hebron Institute of Oncology, Barcelona, and colleagues reported a significant improvement in median progression-free survival in patients with high-risk biomarkers following treatment with amivantamab plus lazertinib.
The phase III MARIPOSA trial enrolled patients with treatment-naive, EGFR-mutant advanced NSCLC. A total of 858 patients were either randomly assigned to receive amivantamab plus lazertinib (n = 429) or osimertinib (n = 429). Next-generation sequencing techniques were then used to analyze pathogenic alterations of baseline blood circulating tumor DNA (ctDNA) samples, and the primary study outcome was median progression-free survival.
Overall findings revealed that among patients with TP53 co-mutation, the median progression-free survival was 18.2 months with amivantamab plus lazertinib vs 12.9 months with osimertinib (hazard ratio [HR] = 0.65; P = .003). Additional findings revealed that treatment with amivantamab plus lazertinib significantly improved median progression-free survival in patients with ctDNA clearance at cycle 3 day 1 (24.0 vs 16.5 months; HR = 0.64; P = .004) and in patients who did not clear ctDNA (16.5 vs 9.1 months; HR = 0.48; P = .014). For patients with liver metastases at baseline, amivantamab plus lazertinib significantly prolonged median progression-free survival (18.2 vs 11.0 months; HR = 0.58; P = .017), which was consistent with the improved progression-free survival for patients with a history of brain metastases.
Disclosure: For full disclosures of the study authors, visit coi.asco.org.
JNCCN Spotlights
